Back

A multifactorial porcine model of cardio-metabolic HFpEF highlights miR-483-3p as a promising target therapy

17 May 2025 (14:30 - 14:45)
Organised by: Logo
Congress Presentation Part of: Young Investigator Award (YIA) Basic Science Heart Failure with Preserved Ejection Fraction (HFpEF) HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Miss Katharina Kohlat

German Heart Center Of Charite Berlin (Germany)

3 More presentations in this session

Presentation thumbnail
Dapagliflozin in primary prevention of cardiotoxicity induced by anthracycline-trastuzumab therapy through activation of pAMPK and inhibition of MyD88 and NLRP-3
Doctor V. Quagliariello (Naples, IT)
Abstract Slides Video
Presentation thumbnail
Engineering genetic resilience for cardiometabolic HFpEF: the crucial role of redox homeostasis
Doctor M. Pepin (Stanford, US)
Abstract Slides Video
Presentation thumbnail
Phospholamban antisense therapy reduces phospholamban aggregation and enhances calcium and contractile kinetics in human phospholamban cardiomyopathy
Mr F. Deiman (Groningen, NL)
Abstract Slides Video

Access the full session

Session thumbnail
Young Investigator Award (YIA) Basic Science
Video

The Event

Event poster

Heart Failure 2025

17 May 2025 14:30 CET
You may be interested in
thumbnail
Congress Presentation
A multifactorial porcine model of cardio-metabolic HFpEF highlights miR-483-3p as a promising target therapy
thumbnail
Congress Session
New approaches in the management of heart failure
thumbnail
Congress Session
Basic and Translational Late-Breaking Science

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources